Goktas S (1515. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005;65:1168-72.) |
30 PC |
5.3 ± 1.6 µg / mL |
APN concentrations are lower in PC than BPH or in control subjects |
APN are negatively associated with the histologic grade and disease stage of PC |
CC |
41 BPH |
14.5 ± 4.4 µg / mL |
36 Con |
16.2 ± 4.1 µg / mL |
Michalakis K (1616. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S,Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007;16:308-13.) |
75 PC |
7.4 ± 5.0 µg / mL |
Higher plasma APN concentrations are associated with a reduced risk of PC |
AdipoR1 and AdipoR2 in cancerous were weaker expressed compared with healthy prostate tissue |
CC |
75 BPH |
11.5 ± 6.4 µg / mL |
150 Con |
12.8 ± 8.0 µg / mL |
Schenk JM. (1717. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2009;69:1303-11.) |
698 BPH |
OR = 0.43 |
High APN concentrations were associated with reduced risk of BPH |
Neither C-peptide nor leptin was associated with BPH risk |
NCC |
709 Con |
Li H (1818. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34-43.) |
654 PC |
Q1: 2.7 µg / mL |
Higher APN concentrations have a lower risk for developing high-grade or metastatic cancer |
Leptin was unrelated to PC risk or mortality |
NCC |
644 Con |
Q3: 6.3 µg / mL |
|
Q5: 13.3 µg / mL |
Tan W (1919. Tan W, Wang L, Ma Q, Qi M, Lu N, Zhang L, et al. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation. Prostate. 2015;75:1197-205.) |
96 PC |
Low level of APN |
APN was significantly decreased in PC compared with that of BPH tissues |
APN may function as a tumor suppressor through inhibiting EMT of PC cells. |
CC |
15 BPH |
BPH: 1of 15 (6.7%) GS <7: 6of 27 (22%) |
GS = 7: 18of 26 (69%) |
Decreased APN level was significantly associated with high GS |
GS > 7: 32of43 (74%) |
Medina EA (2222. Medina EA, Shi X, Grayson MH, Ankerst DP, Livi CB, Medina MV, et al. The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:309-15.) |
228 PC |
OR = 0.62 |
Only HMW APN decreased the risk of PC in obese man |
HMW increased the risk of PC in normal and overweight men |
NCC |
239 Con |
Baillargeon J (2323. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006;15:1331-5.) |
125 PC |
17.9 ± 0.6 µg / mL |
APN was not significant associated with PC risk |
BMI was not associated with incident PC |
NCC |
125 Con |
19.9 ± 13.2 µg / mL |
Stevens VL. (2424. Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2014;23:890-2.) |
272 PC |
OR = 1.11 |
APN was not associated with risk of aggressive PC |
C-peptide was not associated with risk of aggressive prostate cancer |
NCC |
272 Con |
Ikeda A. (2525. Ikeda A, Nakagawa T, Kawai K, Onozawa M, Hayashi T, Matsushita Y, et al. Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. Prostate Int. 2015;3:87-92.) |
24 PC |
9.96 µg / mL |
APN was significantly and positively associated with PSA levels |
High APN increased the Incidence of low-or mediate-risk PC in obese man |
CS |
2817 Con |
7.64 µg / mL |